Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Am J Physiol Endocrinol Metab ; 312(1): E48-E57, 2017 01 01.
Article in English | MEDLINE | ID: mdl-27879249

ABSTRACT

Glucosamine is an essential substrate for N-linked protein glycosylation. However, elevated levels of glucosamine can induce endoplasmic reticulum (ER) stress. Glucosamine-induced ER stress has been implicated in the development of diabetic complications, including atherosclerosis and hepatic steatosis. In this study, we investigate the potential relationship between the effects of glucosamine on lipid-linked oligosaccharide (LLO) biosynthesis, N-linked glycosylation, and ER homeostasis. Mouse embryonic fibroblasts (MEFs) were cultured in the presence of 0-5 mM glucosamine for up to 18 h, and LLO biosynthesis was monitored by fluorescence-assisted carbohydrate electrophoresis. ER stress was determined by quantification of unfolded protein response (UPR) gene expression. We found that exposure of MEFs to ≥1 mM glucosamine significantly impaired the biosynthesis of mature (Glc3Man9GlcNAc2) LLOs before the activation of the UPR, which resulted in the accumulation of an LLO intermediate (Man3GlcNAc2). The addition of 4-phenylbutyric acid (4-PBA), a chemical chaperone, was able to alleviate ER stress but did not rescue LLO biosynthesis. Other ER stress-inducing agents, including dithiothreitol and thapsigargin, had no effect on LLO levels. Together, these data suggest that elevated concentrations of glucosamine induce ER stress by interfering with lipid-linked oligosaccharide biosynthesis and N-linked glycosylation. We hypothesize that this pathway represents a causative link between hyperglycemia and the development of diabetic complications.


Subject(s)
Endoplasmic Reticulum Stress/drug effects , Fibroblasts/drug effects , Glucosamine/pharmacology , Glycosylation/drug effects , Lipopolysaccharides/biosynthesis , Animals , Cell Line , Dithiothreitol/pharmacology , Enzyme Inhibitors/pharmacology , Fibroblasts/metabolism , Mice , Phenylbutyrates/pharmacology , Thapsigargin/pharmacology , Unfolded Protein Response/drug effects
2.
Dalton Trans ; 43(13): 4950-61, 2014 Apr 07.
Article in English | MEDLINE | ID: mdl-24481236

ABSTRACT

A series of C-hydroxy carborane derivatives of (S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)-pentanedioic acid were prepared as a new class of boron rich inhibitors of prostate specific membrane antigen (PSMA), which is overexpressed on prostate cancer tumours and metastases. Closo-, nido- and iodo-carborane conjugates were prepared and screened in vitro where the water soluble iodinated cluster had the highest affinity with an IC50 value (73.2 nM) that was comparable to a known PSMA inhibitor 2-(phosphonomethyl)-pentanedioic acid (PMPA, 63.9 nM). The radiolabeled analogue was prepared using (123)I and the biodistribution determined in a prostate cancer model derived from a PSMA positive cell line (LNCaP) at 1, 2, 4, 6 and 24 h post injection (n = 4 per time point). The results showed good initial tumour uptake of 4.17% at 1 h, which remained at that level only decreasing somewhat at 6 h (3.59%). At the latter time point tumour-to-blood and tumour-to-muscle ratios peaked at 3.47 at 25.52 respectively. There was significant off-target binding particularly in the liver and gall bladder and a surprising amount of deiodination in vivo. Notwithstanding, this work demonstrates that carboranes can be used to prepare potent ligands for PSMA creating the opportunity to develop a new class of BNCT agents for prostate cancer.


Subject(s)
Boron Compounds , Glutamate Carboxypeptidase II/antagonists & inhibitors , Animals , Antigens, Surface/metabolism , Boron Compounds/blood , Boron Compounds/chemical synthesis , Boron Compounds/pharmacokinetics , Boron Compounds/pharmacology , Cell Line, Tumor , Gallbladder/metabolism , Glutamate Carboxypeptidase II/metabolism , Humans , Intestinal Mucosa/metabolism , Liver/metabolism , Male , Mice , Mice, Nude , Prostatic Neoplasms/metabolism , Tissue Distribution
3.
Can J Diabetes ; 37(5): 345-50, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24500563

ABSTRACT

Diabetes mellitus is a major independent risk factor for the development of cardiovascular disease, and both type 1 and type 2 diabetes have been shown to accelerate the development of atherosclerosis, the underlying cause of most myocardial infarctions. Despite the profound clinical importance of vascular disease in patients with diabetes mellitus, our understanding of the relative contributions of insulin resistance and hyperglycemia to atherogenesis is not complete. Furthermore, the molecular and cellular pathways that are involved in disease progression are not clear. In this review, we summarize our current understanding of the potential mechanisms that link diabetes to atherosclerosis and indicate existing gaps in our knowledge.


Subject(s)
Atherosclerosis/physiopathology , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Diabetic Angiopathies/physiopathology , Hyperglycemia/physiopathology , Atherosclerosis/blood , Atherosclerosis/prevention & control , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/genetics , Diabetic Angiopathies/blood , Diabetic Angiopathies/genetics , Disease Progression , Endoplasmic Reticulum/metabolism , Female , Humans , Hyperglycemia/blood , Hyperglycemia/genetics , Insulin Resistance/genetics , Male , Oxidative Stress , Risk Factors , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL